Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HT-KAM is a functional proteomic screening technology that enables direct measurement of the catalytic activity of many kinases in parallel7–10.”
From A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors (2023) · cites this paper as [7]
In the citing paper
“The HT-KAM platform uses arrays of peptides that act as sensors of phosphorylation activity7.”
From A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors (2023) · cites this paper as [7]
In the citing paper
“No statistical method was used to predetermine sample size, but our sample sizes are similar to those reported in previous publications6,7,12–14.”
From A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors (2023) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J. A., Thompson, I. R., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1111 · Cited by 4,051
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Self-citationProteogenomic characterization of human colon and rectal cancer
CPTAC, T. N., Zhang, B., Wang, J., Wang, X., Zhu, J., Liu, Q., Shi, Z., Chambers, M. C., Zimmerman, L. J., Shaddox, K. F., et al. (2014) · Nature · doi:10.1038/nature13438 · Cited by 1,462
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
The BioPlex network: a systematic exploration of the human interactome
Huttlin, E. L., Ting, L., Bruckner, R. J., Gebreab, F., Gygi, M. P., Szpyt, J., Tam, S., Zarraga, G., Colby, G., Baltier, K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.06.043 · Cited by 1,425
Research works printed but not linked: 47
- Petricoin, E. F., Zoon, K. C., Kohn, E. C., Barrett, J. C. & Liotta, L. A. Clinical proteomics: translating benchside promise into bedside reality. Nat. Rev. Drug Discov. 1, 683–695 (2002). · DOI · Paper page
- Blume-Jensen, P. & Hunter, T. Oncogenic kinase signalling. Nature 411, 355–365 (2001). · DOI · Paper page
- Fleuren, E. D., Zhang, L., Wu, J. & Daly, R. J. The kinome ‘at large’ in cancer. Nat. Rev. Cancer 16, 83–98 (2016). · DOI · Paper page
- Johnson, S. A. & Hunter, T. Kinomics: methods for deciphering the kinome. Nat. Methods 2, 17–25 (2005). · DOI · Paper page
- Krogan, N. J., Lippman, S., Agard, D. A., Ashworth, A. & Ideker, T. The Cancer Cell Map Initiative: defining the hallmark networks of cancer. Mol. Cell 58, 690–698 (2015). · DOI · Paper page
- Hoadley, K. A. et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158, 929–944 (2014). · DOI · Paper page
- Akbani, R. et al. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat. Commun. 5, 3887 (2014). · DOI · Paper page
- Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347, 1260419 (2015). · DOI · Paper page
- Drake, J. M. et al. Phosphoproteome integration reveals patient-specific networks in prostate. Cancer Cell 166, 1041–1054 (2016).
- Sharma, K. et al. Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep. 8, 1583–1594 (2014). · DOI · Paper page
- Sos, M. L. et al. Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Rep. 8, 1037–1048 (2014). · DOI · Paper page
- Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035–1044 (2007). · DOI · Paper page
- Kubota, K. et al. Sensitive multiplexed analysis of kinase activities and activity-based kinase identification. Nat. Biotechnol. 27, 933–940 (2009). · DOI
- Nomura, D. K., Dix, M. M. & Cravatt, B. F. Activity-based protein profiling for biochemical pathway discovery in cancer. Nat. Rev. Cancer 10, 630–638 (2010). · DOI · Paper page
- Ren, W., Damayanti, N. P., Wang, X. & Irudayaraj, J. M. Kinase phosphorylation monitoring with i-motif DNA cross-linked SERS probes. Chem. Commun. (Camb.) 52, 410–413 (2016). · doi:10.1039/c5cc06566f
- Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H. & Peterson, J. R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1039–1045 (2011). · DOI · Paper page
- Houseman, B. T., Huh, J. H., Kron, S. J. & Mrksich, M. Peptide chips for the quantitative evaluation of protein kinase activity. Nat. Biotechnol. 20, 270–274 (2002). · DOI · Paper page
- Fang, C. et al. Integrated microfluidic and imaging platform for a kinase activity radioassay to analyze minute patient cancer samples. Cancer Res. 70, 8299–8308 (2010). · DOI
- Li, X. et al. The reverse in-gel kinase assay to profile physiological kinase substrates. Nat. Methods 4, 957–962 (2007). · doi:10.1038/nmeth1106
- Wu, J., Barbero, R., Vajjhala, S. & O’Connor, S. D. Real-time analysis of enzyme kinetics via micro parallel liquid chromatography. Assay Drug Dev. Technol. 4, 653–660 (2006). · doi:10.1089/adt.2006.4.653
- Sanz, A. et al. Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation. PLoS ONE 6, e18522 (2011). · DOI
- Olow, A. et al. An atlas of the human kinome reveals the mutational landscape underlying dysregulated phosphorylation cascades in cancer. Cancer Res. 76, 1733–1745 (2016). · DOI · Paper page
- Hornbeck, P. V. et al. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 43, D512–D520 (2015). · DOI · Paper page
- Yang, X. et al. Widespread expansion of protein interaction capabilities by alternative splicing. Cell 164, 805–817 (2016). · DOI · Paper page
- Van Geel, R. M., Beijnen, J. H., Bernards, R. & Schellens, J. H. Treatment individualization in colorectal cancer. Curr. Colorectal Cancer Rep. 11, 335–344 (2015). · DOI
- Ursem, C., Atreya, C. E. & Van Loon, K. Emerging treatment options for BRAF-mutant colorectal cancer. Gastrointest. Cancer 8, 13–23 (2018).
- Bernards, R. A missing link in genotype-directed cancer therapy. Cell 151, 465–468 (2012). · DOI
- Larkin, J. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Eng. J. Med. 371, 1867–1876 (2014). · DOI · Paper page
- Van Allen, E. M. et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 4, 94–109 (2014). · DOI · Paper page
- Kemper, K. et al. BRAF(V600E) kinase domain duplication identified in therapy-refractory melanoma patient-derived xenografts. Cell Rep. 16, 263–277 (2016). · DOI · Paper page
- Janne, P. A., Gray, N. & Settleman, J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat. Rev. Drug Discov. 8, 709–723 (2009). · DOI · Paper page
- Ruiz-Saenz, A. & Moasser, M. M. Targeting HER2 by combination therapies. J. Clin. Oncol. 36, 808–811 (2018). · DOI
- Cohen, R. L. & Settleman, J. From cancer genomics to precision oncology—tissue’s still an issue. Cell 157, 1509–1514 (2014). · DOI
- Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714–726 (2013). · DOI · Paper page
- Kemper, K. et al. Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts. EMBO Mol. Med. 7, 1104–1118 (2015). · DOI · Paper page
- Breitinger, H.-G. Drug Synergy—Mechanisms and Methods of Analysis (InTech, 2012). · DOI
- Chou, T. C. & Talalay, P. Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27–55 (1984). · DOI · Paper page
- Berenbaum, M. C. Synergy, additivism and antagonism in immunosuppression. A critical review. Clin. Exp. Immunol. 28, 1–18 (1977).
- Berenbaum, M. C. What is synergy? Pharmacol. Rev. 41, 93–141 (1989).
- Bliss, W. L. Early man in western and northwestern Canada. Science 89, 365–366 (1939). · doi:10.1126/science.89.2312.365-a
- Arao, T. et al. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res. 64, 9101–9104 (2004). · DOI
- Daemen, A. et al. Modeling precision treatment of breast cancer. Genome Biol. 14, R110 (2013). · DOI · Paper page
- Moasser, M. M., Srethapakdi, M., Sachar, K. S., Kraker, A. J. & Rosen, N. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res. 59, 6145–6152 (1999).
- Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973–977 (2010). · DOI · Paper page
- Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427–430 (2010). · DOI · Paper page
- Mori, M., Pan, B. & Coppé, J. P. High-throughput kinase activity mapping (HT-KAM) system: biochemical assay. Nat. Protoc. Exch. https://doi.org/10.1038/protex.2019.029 (2019). · DOI · Paper page
- Yau, C., Wolf, D. M. & Coppé, J. P. High-throughput kinase activity mapping (HT-KAM) system: analysis of phospho-catalytic profiles. Nat. Protoc. Exch. https://doi.org/10.1038/protex.2019.030 (2019). · DOI · Paper page
Cited by
Ruiz-Saenz, A., Atreya, C. E., Wang, C., Pan, B., Dreyer, C. A., Brunen, D., Prahallad, A., Muñoz, D. P., Ramms, D. J., Burghi, V., et al. (2023) · Nature Cancer · doi:10.1038/s43018-022-00508-5 · Cited by 39
“The HT-KAM platform uses arrays of peptides that act as sensors of phosphorylation activity 7 .”
InfluentialSelf-citation
Metadata
- Authors
- Coppé, J.-P., Mori, M., Pan, B., Yau, C., Wolf, D. M., Ruiz-Saenz, A., Brunen, D., Prahallad, A., Cornelissen-Steijger, P., Kemper, K., Posch, C., Wang, C., Dreyer, C. A., Krijgsman, O., Lee, P. R. E., Chen, Z., Peeper, D. S., Moasser, M. M., Bernards, R., & van ‘t Veer, L. J.
- Venue
- Nature Cell Biology
- Published
- 2019-06
- Volume
- 21
- Issue
- 6
- Pages
- 778-790
- ISSN
- 1465-7392
- 1476-4679
- Cited by
- 36
- References
- 23
- Language
- en
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities. https://app.cochat.ai/papers/10.1038/s41556-019-0328-z
- The paper
- Coppé, J.-P., Mori, M., Pan, B., Yau, C., Wolf, D. M., Ruiz-Saenz, A., Brunen, D., Prahallad, A., Cornelissen-Steijger, P., Kemper, K., Posch, C., Wang, C., Dreyer, C. A., Krijgsman, O., Lee, P. R. E., Chen, Z., Peeper, D. S., Moasser, M. M., Bernards, R., & van ‘t Veer, L. J. (2019). Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities. Nature Cell Biology. https://doi.org/10.1038/s41556-019-0328-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.